Polyrizon Ltd.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PLRZ research report →
Price Chart
About the company
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue.
- CEO
- Tomer Izraeli
- IPO
- 2024
- Employees
- 6
- HQ
- Ra'anana, TA, IL
Get TickerSpark's AI analysis on PLRZ
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.43M
- P/E
- -2.42
- PEG
- -0.02
- P/S
- 0.00
- P/B
- 0.82
- EV/EBITDA
- -0.32
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -24.10%
- ROIC
- -52.17%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-342,000-189.8%
- Op Income
- $-6,249,000
- Net Income
- $-3,335,000-115.9%
- EPS
- $-2.07+98.5%
- OCF Growth
- -294.8%
- FCF Growth
- -295.4%
- 52W High
- $18.20
- 52W Low
- $2.88
- 50D MA
- $10.26
- 200D MA
- $12.37
- Beta
- -1.34
- RSI (14)
- 47
- Avg Volume
- 38.50K
No earnings-call transcripts are available for PLRZ yet.
- Free Float
- 93.9%
- Shares Outstanding
- 1.12M
- Float Shares
- 1.05M
of shares held by institutions
4 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Izraeli Tomer | sell | 500 |
| Mar 31, 26 | Carmel Liron | sell | 942 |
| Mar 31, 26 | Adler Oz | sell | 3,292 |
| Mar 30, 26 | Carmel Liron | sell | 100 |
| Mar 30, 26 | Izraeli Tomer | sell | 3,900 |
| Mar 30, 26 | Turgeman Tidhar | sell | 2,917 |
| Mar 18, 26 | Vinokur Yehonatan Zalman | other | 0 |
| Mar 18, 26 | Vinokur Yehonatan Zalman | other | 0 |
| Mar 18, 26 | Carmel Liron | other | 0 |
| Mar 18, 26 | Carmel Liron | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PLRZ coverage
Recent articles, reports, and earnings notes.
No research on PLRZ yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PLRZ report →POLYRIZON ADOPTS LIMITED DURATION SHAREHOLDER RIGHTS PLAN
globenewswire.com · Nov 9
Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker
globenewswire.com · Oct 27
Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform
globenewswire.com · Oct 5
Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker
globenewswire.com · Sep 22
Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement
globenewswire.com · Sep 4
Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement
globenewswire.com · Sep 3
Polyrizon Completes All Five U.S. Site Contracts for NASARIX™ First-in-Human Allergy Study
globenewswire.com · Sep 2
Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment
globenewswire.com · Aug 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.